Journal
TRENDS IN MOLECULAR MEDICINE
Volume 20, Issue 6, Pages 332-342Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2014.02.007
Keywords
cancer; Mucin 1 (MUC1); VNTR; ABC pumps; cancer stem cell; EMT
Funding
- NCI NIH HHS [R03 CA166910, R15 CA173668, R01 CA118944] Funding Source: Medline
Ask authors/readers for more resources
The transmembrane glycoprotein Mucin (MUC1) is aberrantly glycosylated and overexpressed in a variety of epithelial cancers, and plays a crucial role in progression of the disease. Tumor-associated MUC1 differs from the MUC1 expressed in normal cells with regard to its biochemical features, cellular distribution, and function. In cancer cells, MUC1 participates in intracellular signal transduction pathways and regulates the expression of its target genes at both the transcriptional and post-transcriptional levels. This review highlights the structural and functional differences that exist between normal and tumor-associated MUC1. We also discuss the recent advances made in the use of MUC1 as a biomarker and therapeutic target for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available